Hepatitis C virus: standard-of-care treatment
- PMID: 23886001
- DOI: 10.1016/B978-0-12-405880-4.00005-6
Hepatitis C virus: standard-of-care treatment
Abstract
Hepatitis C virus (HCV) infection is curable by therapy. The antiviral treatment of chronic hepatitis C has been based for decades on the use of interferon (IFN)-α, combined with ribavirin. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) and host-targeted agents (HTA). A new standard-of-care treatment has been approved in 2011 for patients infected with HCV genotype 1, based on a triple combination of pegylated IFN-α, ribavirin, and either telaprevir or boceprevir, two inhibitors of the HCV protease. New triple and quadruple combination therapies including pegylated IFN-α, ribavirin, and one or two DAAs/HTAs, respectively, are currently being evaluated in Phase II and III clinical trials. In addition, various options for all-oral, IFN-free regimens are currently being evaluated. This chapter describes the characteristics of the different drugs used in the treatment of chronic hepatitis C and those currently in development and provides an overview of the current and future standard-of-care treatments of chronic hepatitis C.
Keywords: Direct-acting antivirals; Hepatitis C virus; Interferon alpha; Interferon-free regimens; Ribavirin.
© 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Future perspectives: towards interferon-free regimens for HCV.Antivir Ther. 2012;17(6 Pt B):1201-10. doi: 10.3851/IMP2431. Epub 2012 Oct 5. Antivir Ther. 2012. PMID: 23186654 Review.
-
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.J Infect. 2014 Jan;68(1):1-20. doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4. J Infect. 2014. PMID: 24012819 Review.
-
Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).J Hepatol. 2014 Jul;61(1):7-14. doi: 10.1016/j.jhep.2014.03.011. Epub 2014 Mar 17. J Hepatol. 2014. PMID: 24650691
-
[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].Harefuah. 2012 Dec;151(12):709-14, 719. Harefuah. 2012. PMID: 23330266 Hebrew.
-
A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16. Clin Gastroenterol Hepatol. 2013. PMID: 23602817
Cited by
-
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.Antimicrob Agents Chemother. 2014 Jun;58(6):3451-60. doi: 10.1128/AAC.02619-14. Epub 2014 Apr 7. Antimicrob Agents Chemother. 2014. PMID: 24709263 Free PMC article.
-
An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs.BMC Complement Med Ther. 2021 Oct 12;21(1):260. doi: 10.1186/s12906-021-03408-w. BMC Complement Med Ther. 2021. PMID: 34641875 Free PMC article.
-
Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities.Mol Pharm. 2023 Aug 7;20(8):3698-3740. doi: 10.1021/acs.molpharmaceut.2c01080. Epub 2023 Jul 24. Mol Pharm. 2023. PMID: 37486263 Free PMC article. Review.
-
Discovery, Optimization, and Clinical Application of Natural Antimicrobial Peptides.Biomedicines. 2021 Oct 3;9(10):1381. doi: 10.3390/biomedicines9101381. Biomedicines. 2021. PMID: 34680498 Free PMC article. Review.
-
Neoboutonia melleri var velutina Prain: in vitro and in vivo hepatoprotective effects of the aqueous stem bark extract on acute hepatitis models.BMC Complement Altern Med. 2018 Jan 22;18(1):24. doi: 10.1186/s12906-018-2091-2. BMC Complement Altern Med. 2018. PMID: 29357846 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
